Navigation Links
Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials
Date:6/4/2011

CHICAGO, June 4, 2011 /PRNewswire/ -- Data presented at the 47th American Society of Clinical Oncology (ASCO) annual meeting demonstrate the potential of circulating tumor cells (CTC) as a biomarker for metastatic prostate cancer clinical trials.  This study represents the first randomized, double-blind, placebo controlled Phase III trial to evaluate CTCs as a potential biomarker for overall survival.  Biomarkers are of scientific interest as, if validated, they could be used as a surrogate for a clinical endpoint and may help accelerate the clinical trial process.  

Results of the study titled, "Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC)" indicated that pre-treatment, CTCs and lactate dehydrogenase (LDH), both alone and in combination, were prognostic biomarkers, while baseline prostate-specific antigen (PSA) was not.  Following the start of treatment, CTC counts were measured at four, eight and 12 weeks.  The data suggest that changes in CTC counts can predict overall survival during treatment.  Data also indicated LDH was strongly associated with survival.  

"Establishing CTCs as a biomarker or part of a biomarker panel that is a surrogate-endpoint for survival would be an important step toward our goal of enabling shorter trials and more rapid drug approvals in prostate cancer," said Howard Scher, M.D., the lead author of the study and chief of the genitourinary oncology service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan-Kettering Cancer Center. 

"As the only device with regulatory clearance to capture and count CTCs, we are excited that the data substantiates the prognostic value of CELLSEARCH®," said Robert McCormack, Ph.D. and Head of Technology Innovation at Veridex, LLC.  "We look forward to further investigating the potential predictive benefit of CTCs in metastatic prostate cancer clinical trials as there are limited ways of assessing therapeutic benefit in this disease, especially when it has metastasized to the bone."

Additional studies are underway to further validate CTCs as a surrogate endpoint in metastatic prostate cancer studies.

Study Design

The CTC analysis was conducted to determine if CTCs could be used as a surrogate for overall survival.  It was performed in 900 of the 1195 enrolled study patients with metastatic castration-resistant prostate cancer post-docetaxel being treated with either abiraterone acetate plus prednisone or placebo plus prednisone.  CTCs were counted (cells/7.5 mL) along with other biomarkers including PSA, LDH, hemoglobin, alkaline phosphatase at screening and baseline and post-baseline at four, eight and 12 weeks. Analyses were conducted for these biomarkers individually and collectively.

Veridex provided product support for the study. 

Dr. Howard Scher has provided consulting services to the company. 

Additional Data Presented at ASCO Substantiates In Vitro Diagnostic Use of CELLSEARCH® CTC Test

An independent study investigating the in vitro diagnostic use of CTC testing found that the number of CTCs in the blood may help physicians more reliably assess treatment benefit for patients with metastatic breast cancer.  The study, a large-scale retrospective analysis using blinded data to create a pooled dataset of 841 patients from cancer centers around the world, found that CTC count at or above the threshold of five was reliably associated with disease progression.  Further, the predictive value of CTCs was not affected by treatment type (chemotherapy, endocrine therapy, biologic therapy), tumor type (hormone receptor positive/negative, HER2 positive/negative), or sites of disease involvement.  The study was lead by Minetta Liu, M.D., Georgetown Lombardi Comprehensive Cancer Center and will be presented during a poster session on Monday, June 6th, 2011.

Dr. Minetta Liu has provided consulting services to the company. 

About Circulating Tumor Cells

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream.  The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

About CELLSEARCH® CTC Test

CELLSEARCH® is the first and only regulatory-cleared in vitro diagnostic test to capture and count CTCs to determine the prognosis of patients with metastatic breast, colorectal or prostate cancer.  The test can be administered at any time during the course of therapy as a routine blood test.  It is used in combination with other tests and a clinician's assessment, to provide a more complete picture of a patient's prognosis.

About Veridex, LLC

Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians with high-value diagnostic oncology products.  Veridex's IVD products may significantly benefit patients by helping physicians make more informed decisions that enable better patient care.  Veridex's Clinical Research Solutions provide tools and services that may be used for the selection, identification and enumeration of targeted rare cells in peripheral blood for the identification of biomarkers, aiding scientists in their search for new, targeted therapies.  For more information, visit www.veridex.com

About Abiraterone

In the U.S., abiraterone acetate is marketed as ZYTIGA™ by Centocor Ortho Biotech, Inc. an affiliate of Veridex.  It was developed by Ortho Biotech Oncology Research & Development, unit of Cougar Biotechnology, Inc. and was approved by the U.S. Food & Drug Administration on April 28, 2011.  Marketing authorization applications for ZYTIGA have been filed with other regulatory authorities around the world.  For more information about ZYTIGA, visit www.ZYTIGA.com.


'/>"/>
SOURCE Veridex, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
2. American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA
3. American Stroke Association Late-Breaking Science Report: Antiplatelet Drug May Be Better Than Aspirin in Preventing Recurrent Strokes
4. American Heart Association Late-Breaking Clinical Trial Report: New Reversible Oral Drug Reduces Cardiac Events in Primary PCI Patients
5. American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis
6. MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
7. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
8. Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
9. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
10. Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting
11. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... WELLESLEY, Massachusetts , May 26, 2016 ... sequencing (NGS) has matured into an essential life science ... research and development applications. BCC Research reveals in its ... of a second growth phase, one powered by a ... applied fields.      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ...
(Date:5/25/2016)... , May 25, 2016  Zymo Research Corp. ... their new reference materials that help researchers obtain ... collection to analyses. The rapid growth of the ... researchers to have standard methods to improve the ... Biases inherently exist at every step of the ...
(Date:5/25/2016)... Digital Health Dialog, LLC dba EngagedMedia ... US Patent and Trademark Office of U.S. Patent ... for electronic opt-­in and processing of discount coupons ... compliance and otherwise. Logo - http://photos.prnewswire.com/prnh/20160524/371583LOGO ... "Our technology allows for individuals to opt­-in to ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 2016 , ... Cardiac arrhythmia is a common complication following ... survival, reports a team of UPMC researchers in the largest study of its ... Thoracic and Cardiovascular Surgery, provide critical information that will hopefully lead to better ...
(Date:5/26/2016)... ... 26, 2016 , ... MadgeTech will be showcasing its line of data ... Hampshire at the MadgeTech headquarters. With products sold in more than 100 countries around ... including NASA. , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech ...
(Date:5/26/2016)... Farmingdale, NY (PRWEB) , ... May 26, 2016 ... ... and Hereditary Retinal Degeneration” for the Foundation Fighting Blindness, Long Island Chapter on ... free to the public. , Dr. Maisel, founder of Retina Group of ...
(Date:5/26/2016)... ... ... In an effort to provide hair restoration information to the widest possible audience, Dr. Parsa ... not use the app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making ... , Dr. Mohebi says, “The positive response to the Snapchat videos we started last month ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... of healthcare supply chain solutions, today announced the organization has earned its ISO ... international standards and is compliant with all rules and policies associated with ISO ...
Breaking Medicine News(10 mins):